PDGFRA and gastrointestinal stromal tumor: Since the introduction of imatinib, a tyrosine kinase inhibitor (TKI) that targets Brc-Abl (Philadelphia), KIT, and PDGFRA, the treatment of GIST patients with locally advanced and metastatic disease has dramatically improved.